Batu Biologics Files IND Application for ValloVax

Batu Biologics Submits Investigational New Drug Application For Lung Cancer Anti-Angiogenic Immunotherapy with FDA

Batu Biologics, a biotechnology company focusing on developing therapies that target the Achilles Heel of Cancer: the tumor blood vessels, announced today the filing of an Investigational Drug Application (IND) with the U.S. Food and Drug Administration (FDA) for its lead immune therapy, ValloVax.

Read the full article at

Batu Biologics appoints Chief Financial Officer

Batu Biologics Appoints Gerry Berg as Chief Financial Officer
Seasoned executive to leverage experience in promising new immunotherapy venture

Batu Biologics, a San Diego based immunotherapy company working to develop therapeutics targeting the tumor vasculature, announced today the appointment of Gerry Berg as Chief Financial Officer.

Read the full article at